Delineating structural functionalities of lenacapavir amenable to modifications for targeting emerging drug-resistant HIV-1 capsid variants.
Preprint
- 1 July 2025
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
Lenacapavir (LEN, Gilead Sciences) is a recently discovered, first-in-class, long acting, and ultra-potent HIV-1 capsid (CA)-targeting inhibitor for treatment of multi-drug-resistant HIV-1 infections. LEN exhibits high potency against all major HIV-1 types including the viral variants resistant to current antiretroviral therapies. Accordingly, LEN provides a lifesaving therapy for heavily treatment-experienced adults with multi-drug-resistant HIV-1. However, one notable shortcoming is a relatively low barrier of viral resistance to LEN. The clinical trials have identified resistance-associated mutations near the LEN binding site on HIV-1 CA including M66I, Q67H/K/N, K70R/H/N/S, N74D/H/K, A105S/T and T107N/A/C/S changes. Of these, the M66I variant exhibited the highest level of resistance (>3,200-fold) to LEN. These findings necessitate continuing medicinal chemistry efforts to develop next-generation HIV-1 CA inhibitors against the emerging LEN resistant mutation. Here, our SAR studies have focused on the identification of LEN structural functionalities amenable to modifications and the development of a LEN analog with improved antiviral activity against the M66I mutant virus. We report a new LEN analog, KFA-027, with substantially improved antiviral activity (EC50 of ~444 nM, >20-fold) against HIV-1(M66I CA) compared to the parent LEN. Overall, our findings suggest a route for the future development of improved analogs against WT and emerging drug-resistant CA mutations.Keywords
All Related Versions
- Version 1, 2025-07-01, ChemRxiv
- Published version: ACS Medicinal Chemistry Letters, 16 (10), 2007.
Funding Information
- National Institute of Health Sciences (R21 AI174866)
- National Institute of Health Sciences (RO1 AI157802)
- National Institute of Health Sciences (R01 AI162665)
This publication has 17 references indexed in Scilit:
- Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsThe Journal of Infectious Diseases, 2025
- The HIV-1 Capsid-Targeted Inhibitor GSK878 Alters Selection of Target Sites for HIV DNA IntegrationAIDS Research and Human Retroviruses, 2024
- Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialThe Lancet HIV, 2023
- Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor LenacapavirThe Journal of Infectious Diseases, 2022
- Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical studyJournal of Antimicrobial Chemotherapy, 2022
- Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA databaseInternational Journal of Antimicrobial Agents, 2021
- Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO RegistryOpen Forum Infectious Diseases, 2020
- Clinical targeting of HIV capsid protein with a long-acting small moleculeNature, 2020
- HIV-1 capsid: the multifaceted key player in HIV-1 infectionNature Reviews Microbiology, 2015
- The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of BasesSynthetic Communications, 1981